Rivaroxaban 10mg/d in severe renal failure does not prevent ischemic events in premorbid neurologic disease

Stöllberger, Claudia; Finsterer, Josef

doi:10.1016/j.pjnns.2015.04.002

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to these subgroup analyses, there is one published case report from Austria of an 82-year-old woman with a history of NVAF treated with rivaroxaban, which appeared to be ineffective 30. The patient was given rivaroxaban therapy at 10 mg daily after hospitalization for ischemic stroke, and it was reported that she was unable to achieve stable INR with warfarin therapy.…”

Section: Resultsmentioning

confidence: 99%

Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence

Willett

Morrill

2017

TCRM

View full text Add to dashboard Cite

BackgroundThe use of direct oral anticoagulants (DOACs) is restricted by the limitations of clinical trials guiding therapy for patients with renal impairment, as many of these trials excluded patients with severe renal impairment. There are currently four agents available: dabigatran, rivaroxaban, apixaban, and edoxaban. The purpose of this review was to 1) describe current recommended dosing for each DOAC and published postmarketing data, including case reports, on the use of these agents in the renally impaired; and 2) discuss patient adherence and satisfaction and the cost of these agents.Materials and methodsA literature search was conducted using Medline and Embase with the terms “dabigatran” or “rivaroxaban” or “apixaban” or “edoxaban” and “renal impairment”. Clinical trials and case reports describing the use of DOAC therapy in patients with renal impairment were reviewed. A second search was conducted to find articles evaluating patient adherence, patient satisfaction, and pharmacoeconomics of DOACs.ResultsThere are a multitude of subgroup and post hoc analyses, as well as six case reports with dabigatran and one case report with apixaban, that provide insight for the clinical use of DOACs in patients with renal impairment. Dabigatran exhibits the greatest level of renal elimination, and there are data from clinical trials and several case reports that warrant reconsideration before use. Other DOACs may be a better option in patients with impaired renal function. Further, data from patient-adherence studies have suggested that DOACs that are dosed daily (rather than twice daily) are optimal and preferred. There does not appear to be a cost difference between DOACs and warfarin therapy.ConclusionDOAC therapy in patients with impaired renal function requires more critical review of study data, as these patients may have increased risk of bleeding. It is also valuable to consider patient preferences and cost when selecting the appropriate option for oral anticoagulation.

show abstract

Section: Resultsmentioning

confidence: 99%